Stabilization of nontoxic Ajβ-oligomers: Insights into the mechanism of action of hydroxyquinolines in alzheimer’s disease

Journal of Neuroscience

Volumn 35, Issue 7, 2015, Pages 2871-2884

  Ryan, Timothy M ^a   Roberts, Blaine R ^a   McColl, Gawain ^a   Hare, Dominic J ^a,b   Doble, Philip A ^b   Li, Qiao Xin ^a   Lind, Monica ^a   Roberts, Anne M ^a   Mertens, Haydyn D T ^c   Kirb, Nigel ^c   Pham, Chi L L ^a   Hinds, Mark G ^d,e   Adlard, Paul A ^a   Barnham, Kevin J ^a,d   Curtain, Cyril C ^a   Masters, Colin L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c AUSTRALIAN SYNCHROTRON   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer s disease; Amyloid beta peptide; Hydroxyquinoline; Oligomer; PBT2; Toxicity

Indexed keywords

2 (DIMETHYLAMINO)METHYL 5,7 DICHLORO 8 HYDROXYQUINOLINE; 8 QUINOLINOL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CLIOQUINOL; REACTIVE OXYGEN METABOLITE; THIOFLAVINE; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); PBT2 COMPOUND; PEPTIDE FRAGMENT; PROTEIN BINDING; QUINOLINOL DERIVATIVE; THIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; ELECTRON MICROSCOPY; ELECTROPHORESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANALYSIS; GEL PERMEATION CHROMATOGRAPHY; HUMAN; LASER ABLATION INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY; MASS SPECTROMETRY; MATHEMATICAL MODEL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SEDIMENTATION; SLOT BLOT HYBRIDIZATION; ULTRACENTRIFUGATION; X RAY CRYSTALLOGRAPHY; ANALOGS AND DERIVATIVES; ANIMAL; BIOPHYSICS; BRAIN CORTEX; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; METABOLISM; MOUSE; NERVE CELL; SIZE EXCLUSION CHROMATOGRAPHY; SMALL ANGLE SCATTERING; ULTRASTRUCTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOPHYSICS; CAENORHABDITIS ELEGANS; CELLS, CULTURED; CEREBRAL CORTEX; CHROMATOGRAPHY, GEL; CLIOQUINOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROXYQUINOLINES; MICE; MICROSCOPY, ELECTRON; NEURONS; PEPTIDE FRAGMENTS; PROTEIN BINDING; SCATTERING, SMALL ANGLE; THIAZOLES;

EID: 84923066040     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2912-14.2015     Document Type: Article

References (64)

1. Abramov AY, Canevari L, Duchen MR (2003) Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci 23:5088-5095. Medline
2. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration ofcognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59:43-55. CrossRef Medline
3. Austin C, Hare D, Rozelle AL, Robinson WH, Grimm R, Doble P (2009) Elemental bio-imaging of calcium phosphate crystal deposits in knee samples from arthritic patients. Metallomics 1:142-147. CrossRef Medline
4. Bailey MF, Angley LM, Perugini MA (2009) Methods for sample labeling andmeniscus determinationinthefluorescence-detectedanalyticalultra-centrifuge. Anal Biochem 390:218-220. CrossRefMedline
5. Benilova I, Karran E, De Strooper B (2012) The toxic Abeta oligomer and Alzheimer's disease: an emperor in need ofclothes. Nat Neurosci 15:349357. CrossRefMedline
6. Bernado P, Mylonas E, Petoukhov MV, Blackledge M, Svergun DI (2007) Structural characterization of flexible proteins using small-angle X-ray scattering. J Am Chem Soc 129:5656-5664. CrossRef Medline
7. Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77:71-94. Medline
8. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudiniere R (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A 109:96299634. CrossRefMedline
9. Bush AI (2008) Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 15:223-240. Medline
10. Cheng XR, Sze Hung VW, Scarano S, Mascini M, Minunni M, Kerman K (2012) Label-free methods for probing the interaction of clioquinol with amyloid-[small beta]. Anal Methods 4:2228-2232. CrossRef
11. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676. CrossRef Medline
12. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicao IM, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Wilson A, Grogan DR (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79:785792. CrossRefMedline
13. Coelho T, Maia LF, da Silva AM, Cruz MW, Plante-Bordeneuve V, Suhr OB, Conceicao I, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Grogan DR (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802-2814. CrossRef Medline
14. Colon W, Kelly JW (1992) Partial denaturation oftransthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31:8654-8660. CrossRefMedline
15. Crouch PJ, Savva MS, Hung LW, Donnelly PS, Mot AI, Parker SJ, Greenough MA, Volitakis I, Adlard PA, Cherny RA, Masters CL, Bush AI, Barnham KJ, White AR (2011) The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chap-erone activity. J Neurochem 119:220-230. CrossRef Medline
16. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI (2010) PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J Alzheimers Dis 20:509-516. CrossRef Medline
17. Foss TR, Wiseman RL, Kelly JW (2005) The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry 44:15525-15533. CrossRefMedline
18. Franke D, Svergun DI (2009) DAMMIF, aprogram for rapid ab-initio shape determination in small-angle scattering. J Appl Crystallogr 42:342-346. CrossRef
19. Hare DJ, George JL, Grimm R, Wilkins S, Adlard PA, Cherny RA, Bush AI, Finkelstein DI, Doble P (2010) Three-dimensional elemental bio-imagingofFe, Zn, Cu, MnandP ina6-hydroxydopaminelesionedmouse brain. Metallomics 2:745-753. CrossRefMedline
20. Hare DJ, Grubman A, Ryan TM, Lothian A, Liddell JR, Grimm R, Matsuda T, Doble PA, Cherny RA, Bush AI, White AR, Masters CL, Roberts BR (2013) Profilingtheiron,copperandzinccontentinprimaryneuronand astrocyte cultures by rapid online quantitative size exclusion chromato-graphy-inductively coupled plasma-mass spectrometry. Metallomics 5:1656-1662. CrossRef Medline
21. Hare DJ, Lee JK, Beavis AD, van Gramberg A, George J, Adlard PA, Finkel-stein DI, Doble PA (2012) Three-dimensional atlas ofiron, copper, and zinc in the mouse cerebrum and brainstem. Anal Chem 84:3990-3997. CrossRef Medline
22. Hayden EY, Teplow DB (2013) Amyloid beta-protein oligomers and Alzheimer's disease. Alzheimers Res Ther 5:60. CrossRef Medline
23. Hurshman AR, White JT, Powers ET, Kelly JW (2004) Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 43:7365-7381. CrossRef Medline
24. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271:22908-22914. CrossRef Medline
25. Imbimbo BP, Ottonello S, Frisardi V, Solfrizzi V, Greco A, Seripa D, Pilotto A, Panza F (2012) Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev Clin Immunol 8:135-149. CrossRef Medline
26. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW (2012) The tran-sthyretin amyloidoses: from delineating the molecular mechanism ofag-gregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 421:185-203. CrossRef Medline
27. Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW (2005) Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 38:911-921. CrossRef Medline
28. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736. CrossRefMedline
29. Kenche VB, Zawisza I, Masters CL, Bal W, Barnham KJ, Drew SC (2013) Mixed ligand Cu2+ complexes of a model therapeutic with Alzheimer's amyloid-beta peptide and monoamine neurotransmitters. Inorg Chem 52:4303-4318. CrossRef Medline
30. Kirby NM, Mudie ST, Hawley AM, Cookson DJ, Mertens HDT, Cowieson N, Samardzic-Boban V (2013) A low-background-intensity focusing small-angle X-ray scattering undulator beamline. J Appl Crystallogr 46: 1670-1680. CrossRef
31. Kohn JE, Millett IS, Jacob J, Zagrovic B, Dillon TM, Cingel N, Dothager RS, Seifert S, Thiyagarajan P, Sosnick TR, Hasan MZ, Pande VS, Ruczinski I, Doniach S, Plaxco KW (2004) Random-coil behavior and the dimensions of chemically unfolded proteins. Proc Natl Acad Sci USA 101: 12491-12496. CrossRef Medline
32. Konarev PV, Volkov VV, Sokolova AV, Koch MHJ, Svergun DI (2003) PRIMUS: a Windows PC-based system for small-angle scattering data analysis. J Appl Crystallogr 36:1277-1282. CrossRef
33. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:6448-6453. CrossRef Medline
34. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008)Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7:779-786. CrossRef Medline
35. Lear J, Hare DJ, Fryer F, Adlard PA, Finkelstein DI, Doble PA (2012) Highresolution elemental bioimaging of Ca, Mn, Fe, Co, Cu, and Zn employing LA-ICPMS and hydrogen reaction gas. Anal Chem 84:6707-6714. CrossRefMedline
36. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-357. CrossRefMedline
37. LeVineH 3rd, Ding Q, Walker JA, Voss RS, Augelli-Szafran CE (2009) Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oli-gomer assembly. Neurosci Lett 465:99-103. CrossRefMedline
38. Lim NK, Villemagne VL, Soon CP, Laughton KM, Rowe CC, McLean CA, Masters CL, Evin G, Li QX (2011) Investigation of matrix metallopro-teinases, MMP-2 andMMP-9, inplasmareveals adecrease ofMMP-2 in Alzheimer's disease. J Alzheimers Dis 26:779-786. CrossRefMedline
39. Liu Y, Carver JA, Calabrese AN, Pukala TL (2014) Gallic acid interacts with alpha-synuclein to preventthe structural collapse necessaryforits aggregation. Biochim Biophys Acta 1844:1481-1485. CrossRefMedline
40. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82:4245-4249. CrossRef Medline
41. Matlack KE, Tardiff DF, Narayan P, Hamamichi S, Caldwell KA, Caldwell GA, Lindquist S (2014) Clioquinolpromotes the degradationofmetal-dependent amyloid-beta (Abeta) oligomers to restore endocytosis and ameliorate Abeta toxicity. Proc Natl Acad Sci U S A 111:4013-4018. CrossRefMedline
42. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330:1774. CrossRefMedline
43. McColl G, Roberts BR, Gunn AP, Perez KA, Tew DJ, Masters CL, Barnham KJ, Cherny RA, Bush AI (2009) The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. J Biol Chem 284:22697-22702. CrossRefMedline
44. McColl G, Roberts BR, Pukala TL, Kenche VB, Roberts CM, Link CD, Ryan TM, Masters CL, Barnham KJ, Bush AI, Cherny RA (2012) Utilityofan improvedmodel ofamyloid-beta(Abeta1-42) toxicityinCaenorhabditis elegans for drug screening for Alzheimer's disease. Mol Neurodegener7:57. CrossRefMedline
45. Mok YF, Ryan TM, Yang S, Hatters DM, Howlett GJ, Griffin MD (2011)Sedimentation velocity analysis of amyloid oligomers and fibrils using fluorescence detection. Methods 54:67-75. CrossRefMedline
46. Opazo C, Luza S, Villemagne VL, Volitakis I, Rowe C, Barnham KJ, Strozyk D, Masters CL, Cherny RA, Bush AI (2006) Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. Aging Cell 5:69-79. CrossRefMedline
47. Padmanabhan G, Becue I, Smith J (1989) Clioquinol. In: Analytical profiles of drug substances (Klauss E, Florey E, eds). San Diego: Academic.
48. Petoukhov MV, Franke D, Shkumatov AV, Tria G, Kikhney AG, Gajda M, Gorba C, Mertens HD, Konarev PV, Svergun DI (2012) New developments in the ATSAS program package for small-angle scattering data analysis. J Appl Crystallogr 45:342-350. CrossRef Medline
49. Petoukhov MV, Konarev PV, Kikhney AG, Svergun DI (2007) ATSAS 2.1: towards automated and web-supported small-angle scattering data analysis. J Appl Crystallogr 40:S223-S228.
50. Rembach A, Hare DJ, Doecke JD, Burnham SC, Volitakis I, Fowler CJ, Cherny RA, McLean C, Grimm R, Martins R, Ames D, Masters CL, Bush AI, Roberts BR (2014) Decreased serum zinc is an effect of ageing and not Alzheimer's disease. Metallomics 6:1216-1219. CrossRef Medline
51. Ryan TM, Caine J, Mertens HD, Kirby N, Nigro J, Breheney K, Waddington LJ, Streltsov VA, Curtain C, Masters CL, Roberts BR (2013a) Ammonium hydroxide treatment of Abeta produces an aggregate free solution suitable for biophysical and cell culture characterization. PeerJ 1:73. CrossRefMedline
52. Ryan TM, Friedhuber A, Lind M, Howlett GJ, Masters C, Roberts BR (2012) Small amphipathic molecules modulate secondarystructure and amyloid fibril-forming kinetics of Alzheimer disease peptide Abeta(1-42). J Biol Chem 287:16947-16954. CrossRef Medline
53. Ryan TM, Griffin MD, Bailey MF, Schuck P, Howlett GJ (2011) NBD-labeled phospholipid accelerates apolipoprotein C-II amyloid fibril formation but is not incorporated into mature fibrils. Biochemistry 50: 9579-9586. CrossRefMedline
54. Ryan TM, Roberts BR, Streltsov VA, Nuttall SD, Masters CL (2013b) The role of Aß in Alzheimer's disease: amyloid fibrils and prefibrillar aggregates. New York: Wiley-VCH Verlag.
55. Schuck P (2000) Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J 78:1606-1619. CrossRef Medline
56. Schuck P (2003) On the analysis of protein self-association by sedimentation velocity analytical ultracentrifugation. Anal Biochem 320:104-124. CrossRefMedline
57. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14:837-842. CrossRefMedline
58. Streltsov VA, Varghese JN, Masters CL, Nuttall SD (2011) Crystal structure ofthe amyloid-beta p3 fragment provides a model for oligomer formation in Alzheimer's disease. J Neurosci 31:1419-1426. CrossRef Medline
59. Svergun ND (1992) Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J Appl Crystallogr 25:495-503. CrossRef
60. Tardiff DF, Tucci ML, Caldwell KA, Caldwell GA, Lindquist S (2012) Different 8-hydroxyquinolines protect models ofTDP-43 protein, alpha-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem 287:4107-4120. CrossRef Medline
61. Tayeb HO, Murray ED, Price BH, Tarazi FI (2013) Bapineuzumab and so-lanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Expert Opin Biol Ther 13:1075-1084. CrossRef Medline
62. Telpoukhovskaia MA, Rodriguez-Rodriguez C, Cawthray JF, Scott LE, Page BD, Ali-Torres J, Sodupe M, Bailey GA, Patrick BO, Orvig C (2014) 3-Hydroxy-4-pyridinone derivatives as metal ion and amyloid binding agents. Metallomics 6:249-262. CrossRefMedline
63. Vistica J, Dam J, Balbo A, Yikilmaz E, Mariuzza RA, Rouault TA, Schuck P (2004) Sedimentation equilibrium analysis of protein interactions with global implicit mass conservation constraints and systematic noise decomposition. Anal Biochem 326:234-256. CrossRefMedline
64. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, Masters CL (2006) Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 281:17670-17680. CrossRef Medline